Home >
World Psoriasis Day 2019
2019/10/29
Today, IFPA presents World Psoriasis Day, as an annual day dedicated to people with psoriasis and/or psoriatic arthritis. It has been celebrated on October 29 for more than a decade. On World Psoriasis Day, our member associations and their supporters organise activities around the world to raise awareness of psoriasis.
To see examples of all the activities our members put on in around the world last World Psoriasis Day, visit worldpsoriasisday2018.com.
Aim of World Psoriasis Day
World Psoriasis Day is dedicated to people living with psoriasis or psoriatic arthritis. On October 29, we aim to address their needs:
Raise awareness
Psoriasis affects over 125 million people around the world – not just physically, but also socially, emotionally and financially. World Psoriasis Day aims to raise the profile of this debilitating disease and increase awareness of the effect it has on people’s lives.
Spread information
For many, psoriasis is still a relatively unknown disease. On World Psoriasis Day, IFPA spreads information about psoriasis, dispel common myths and answer questions. They also inform patients about their own condition, so they can feel empowered to speak about it.
Improve access to treatment
On World Psoriasis Day, IFPA lobby to give people with psoriasis better access to appropriate, affordable treatment. That’s why they specifically address key health decision-makers like national governments, policy-makers and healthcare providers that day.
Give the psoriasis community a voice
Many people living with psoriasis may struggle to get the world to listen to their needs. World Psoriasis Day is an opportunity for the psoriasis community to speak out from a common platform – and have its voice heard.
Are there special World Psoriasis Day activities?
Yes! Each year, IFPA member associations organise a wide variety of World Psoriasis Day activities – from small gatherings to large-scale events. Examples of activities include:
Awareness-raising walks or running events
Free information events for the general public
Lectures or seminars held by medical professionals
Handing out flyers and brochures in public places
Drawing competitions
Sending out WPD postcards
Free psoriasis assessment and consultations at hospitals
Activities for children and youth
Photo exhibitions with psoriasis-related themes
Radio or TV interviews with patient leaders or medical experts
Fundraising barbecues, get-togethers or concerts
Outdoor yoga sessions for people with psoriasis
Coverage of World Psoriasis Day by local or national media
Can I join World Psoriasis Day?
Of course! World Psoriasis Day is open to anyone – whether you have psoriasis yourself, know someone who does or simply want to support people living with psoriasis.
To be part of World Psoriasis Day, you can:
Contact your national psoriasis association to find out about their plans for October 29.
Organise an activity yourself. Perhaps your national association isn’t planning anything or you live in a country without an active psoriasis association? Don’t let this stop you! Organising a workshop, an awareness-raising walk, or simply handing out flyers can be a great way to let your community know about World Psoriasis Day. If you organise something, we’d love to hear about it! That way, IFPA can help promote your activity and share some pictures afterwards for our global audience.
Follow IFPA on Facebook or Twitter to get the latest updates on IFPA’s World Psoriasis Day campaigns and plans.
Spread the word about World Psoriasis Day, wear orange and blue on October 29, or reach out to someone from the psoriasis community to let them know you are there for them.
SOURCE: https://ifpa-pso.com/our-actions/world-psoriasis-day/
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Uncovering the mechanism of Jueyin granules in the treatment of psoriasis using network pharmacology.
J Ethnopharmacol.
2020 Nov 15, 262:113214.
Our clinical practice demonstrated that Jueyin granules (JYG) benefit patients with mild to moderate psoriasis vulgaris without apparent adverse effects. JYG have been shown to inhibit epidermal proliferation in an imiquimod (IMQ)-induced psoriasis-like mouse model, as well as keratinocyte proliferation. Moreover, JYG causes no acute or chronic toxicity in animal models. However, its related molecular mechanism has still not been (...)
see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv.
2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)
see on pubmed
In silico data mining of large-scale databases for the virtual screening of human interleukin-2 inhibitors.
Acta Pharm.
2021 Mar 01, 71, (1):33-56.
Interleukin-2 (IL-2) is involved in the activation and differentiation of T-helper cells. Uncontrolled activated T cells play a key role in the pathophysiology by stimulating inflammation and autoimmune diseases like arthritis, psoriasis and Crohn's disease. T cells activation can be suppressed either by preventing IL-2 production or blocking the IL-2 interaction with its receptor. Hence, IL-2 is now emerging as a target for novel therapeutic approaches in several autoimmune disorders. This (...)
see on pubmed
on Atopic Dermatitis
Enhanced Type 2 Immune Reactions by Increased IL-22/IL-22Ra1 Signaling in Chronic Rhinosinusitis With Nasal Polyps.
Allergy Asthma Immunol Res.
2020 Nov , 12, (6):980-993.
Recent studies have revealed the pathogenic role of interleukin (IL)-22 in atopic dermatitis and asthma. However, little is known about the role of IL-22 in the pathophysiology of chronic rhinosinusitis with nasal polyps. We aimed to investigate the expression of IL-22 and its pathogenic function in type 2 immune reactions of nasal polyps (NP).
see on pubmed
Facial Redness in Atopic Dermatitis Patients Treated With Dupilumab: A Case Series.
Seok SH et al.
Facial Redness in Atopic Dermatitis Patients Treated With Dupilumab: A Case Series.
Allergy Asthma Immunol Res.
2020 Nov , 12, (6):1063-1065.
Update on canine filaggrin: a review.
Combarros D et al.
Update on canine filaggrin: a review.
Vet Q.
2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)
see on pubmed
